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Abstract: Semiconductor quantum dots (QDs) are nanometre-scale crystals, which have 
unique photophysical properties, such as size-dependent optical properties, high fluorescence 
quantum yields, and excellent stability against photobleaching. These properties enable 
QDs as the promising optical labels for the biological applications, such as multiplexed 
analysis of immunocomplexes or DNA hybridization processes, cell sorting and tracing,  
in vivo imaging and diagnostics in biomedicine. Meanwhile, QDs can be used as labels for 
the electrochemical detection of DNA or proteins. This article reviews the synthesis and 
toxicity of QDs and their optical and electrochemical bioanalytical applications. Especially 
the application of QDs in biomedicine such as delivering, cell targeting and imaging for 
cancer research, and in vivo photodynamic therapy (PDT) of cancer are briefly discussed.  
Keywords: quantum dots; bioanalysis; toxicology delivery; photodynamic therapy;   
cell imaging 
 
1. Introduction 
Quantum dots (QDs) as colloidal nanocrystalline semiconductors have unique photophysical 
properties due to quantum confinement effects. They emit different wavelengths over a broad range of 
the light spectrum from visible to infrared, depending on their sizes and chemical compositions. 
Compared with the traditional organic fluorophores (e.g., organic dyes and fluorescent proteins), QDs 
have unique optical and electronic properties, such as larger absorption coefficients, size-tunable light 
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emission, superior signal brightness, resistance to photobleaching and simultaneous excitation of 
multiple ﬂuorescence colors [1-6]. In addition, the large-surface area of QDs is beneficial to covalently 
link to biorecognition molecules, such as peptides, antibodies, nucleic acids or small-molecule ligands 
for further application as fluorescent probes (Figure 1).  
Figure 1. Schematic representation of a quantum dot. QDs are nanocrystals composed of a 
core of a semiconductor, usually composed of elements from groups II–IV, e.g., CdSe, or 
groups III–V, e.g., InP. The shell is typically a higher bandgap material such as ZnS. Finally, 
a capping outer layer such as silica can offer large-surface area for covalently linking to 
biorecognition molecules such as peptides, antibodies, nucleic acids and small-molecule 
ligands for further application. The diameter of QDs ranges between 2–10 nm. 
 
 
These properties of QDs herald a revolution from electronic materials science to biological 
applications [7]. Current and projected applications of QDs include using fluorescent labels for cellular 
labeling [1,8,9], intracellular sensors [10,11], deep-tissue and tumor targeting and imaging   
agents [7,12-17], sensitizers for photodynamic therapy (PDT) [18-21], vectors for gene therapy [22-26], 
magnetic resonance imaging (MRI) contrast agents [27,28] and so on. This review mainly summarizes 
the development of synthesis, the surface modification and toxicity of QDs, and briefly focuses on the 
application developments of QDs in the biomedical field. 
2. The Surface Chemistry and Toxicity of QDs  
Early in the 1990s, Bawendi and coworkers first reported a synthesis protocol for QDs with highly 
monodisperse, regular core structure and tunable particle size [29,30]. Up to now, the most successful 
and well-developed method to prepare highly luminescent II–VI QDs is the TOP/TOPO synthetic 
approach [31]. However, these QDs are insoluble in water, which limits their biological applications. 
Therefore, a number of surface functionalization studies have been developed to make QDs   
water-soluble and biologically compatible [29-37]. 
In one common approach, the original hydrophobic coatings are replaced by water-soluble functional 
molecules (e.g., dithiothreitol [38-40], mercaptocarbonic acids [41-44], 2-aminoethanethiol [33,45], 
dihydrolipoic acid [34-36,46,47], oligomeric phosphines [37,48], peptides [49-57], and cross-linked 
dendrons [58-61]) through the ligand exchange reactions. Because the optical properties of the 
inorganic core are often very sensitive to the surface, the ligand exchange process may result in poorer 
performance, particularly in the case of quantum dots [62]. Sensors 2011, 11                                       
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The second approach is to encapsulate QDs in an amphiphile whose hydrophobic ends interleave 
with, but do not replace, the organic coating on QDs. This improvement for QDs synthesis is 
significant: (1) protecting the core/shell structure and maintaining the original photophysics of QDs; 
(2) making QDs water-soluble; (3) providing a biological interface and multiple functions [7]. 
However these kinds of QDs are not stable in biological settings because of relativelyweak anchoring 
of the single and double hydrophobic tails to the particle. Additionally, the hydrophilic end groups of 
even biocompatible surfactants may not protect nanocrystals from nonspeciﬁc biomolecular 
interactions [31]. Scientists have used amphiphilic polymers instead of simple amphiphile because 
single polymer chains can contain multiple hydrophobic units, their interactions with the native 
organic coatings on QDs can be numerous, and thus the encapsulant can be bound more strongly than 
conventional surfactants. However, the range of amphiphilic polymers for creating stable and 
nonaggregating QDs in biological settings has been relatively limited. Up to now, most of the 
amphiphilic polymers used are commercial and their hydrophobic/hydrophilic ratios are ﬁxed, hence 
the cost is high and it may be different to control the process of forming water-soluble QDs and to 
optimize the forming conditions [31]. 
Although QDs have great prospects, the toxicity of QDs cannot be overlooked. During the processing 
of biological applications (e.g., cancer imaging, targeting and PDT treatment), the degradation products 
of QDs will do harm to the cells which they contact with, or produce immune responses with the 
components in blood [17]. The toxic degradation production routes are: first, the oxidation of the 
nanoparticle core/shell material can cause the release of free cadmium or other heavy metals, which 
will interrupt the normal cell activities [18]; secondly, the photosensitized production of reactive 
oxygen intermediates (ROI) also plays an important role in mediating the cell damage [63]; thirdly, the 
toxicity of capping materials should also be considered, several groups in capping materials such as 
mercaptoacetic acid and tri-n-octylphosphine oxide (TOPO) could produce toxicity to cells [12]. 
To reduce the cytotoxicity of QDs, replacement of the cadmium by nontoxic or less-toxic metals 
such as indium (In), or encapsulation of the core with a biocompatibile shell should be considered. 
Though In-based semiconducting dots contain arsenic, another toxin, the cytotoxicity of these dots 
may be small enough to keep the toxicity low. Fisher and coworkers [64] found that QDs could remain 
within the body for very long periods. Kim [8] reported that larger QDs generally accumulated in the 
reticuloendothelial system, such as the liver, spleen and lymphatic system for several months, but the 
size less than 5 nm could be removed by the kidney quickly. So in order to minimize the toxicity of 
QDs, QDs can be designed as smaller as they can, which can help them more easily to clean them out 
from the body. 
In spite of the fact many investigators have paid close attention to and observed the side-effect of 
QDs, the definite metabolism of QDs in vivo remains uncertain [65-68]. Thus, it is still a necessary 
issue to investigate the detailed biochemical and pharmacological mechanism for further application of 
QDs in the human body.  
3. Delivering QDs into Cells 
Effective delivery of QDs into the targeted-cell is the primary requirement for the bioapplications of 
QDs [9,15,17,20,32,54]. It is a major step because if QDs cannot reach their site of action in vivo, they Sensors 2011, 11                                       
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is useless. Furthermore, efficient delivery can also allow a reduction in dosage level, avoid non-specific 
side effects and reduce toxicity risks [66,69,70]. The current methods for delivering QDs into cells 
mainly include passive delivery, facilitated delivery and active delivery. 
The general passive delivery for QDs is endocytosis, which is simple, without further functionalization 
of the QDs surface with a targeting ligand for uptake [66]. By incubating with the cells at appropriate 
concentration and exposure time, QDs will enter into cells though the nonspecific cell endocytosis. 
However, the nonspecific ingestion of this mode caused ineffective endosomal escape, and would 
impede the delivery of QDs to the cytoplasm or other organelles. Furthermore, high intracellular 
concentration of QDs can enhance the cytotoxicity in some cases [69]. 
Facilitated delivery includes four ways: peptide-mediated uptake, protein-mediated delivery, 
polymer-mediated delivery and small molecule-mediated delivery [66]. Generally, these molecules are 
noncovalently assembled onto the surface of QDs for bioconjugation. Facilitated delivery could reduce 
the nonspecific absorption and side effects. However, QDs could also be uptaken by cell through 
endocytosis, leading to endosomal sequestration during the facilitated delivery strategies (Figure 2). As 
is well known, the high acidic of endosomes could degrade the QDs conjugates over time, thus free 
Polyethyleneimine (PEI) was used to encapsule the QDs conjugates to increase the stability [70]. 
Considering further application of cell imaging, more general endosomal escape strategies need to be 
developed in order to expand the application of facilitated delivery. 
Figure 2. Schematic representation of delivering QDs into cells, the process comprises of 
three major stages: (1) endocytosis; (2) sequestering in early endosome (EE); (3) translocation 
to later endosomes (LE) or lysosomes (LS). 
 
Active delivery is a direct physical manipulation of the cell by electroporation and microinjection. 
In comparison to facilitated delivery, QDs conjugates are delivered directly to the cytoplasm via 
electroporation by an endocytic pathway, without subsequent endosomal escape. However, the high 
cellular mortality rate and intracellar aggregation occurring during the delivery should be   
conquered [71]. Compared with electroporation, microinjection could deliver the QDs directly to the 
cytoplasm with lower cell death rate, and the rate of microinjection of QDs conjugates to cells depends 
on the physical constraints of cells, including morphology, membrane thickness, height, etc. [66]. 
Furthermore, this technology is very expensive. Therefore, considering the coexistence of advantages 
and drawbacks of the mentioned approaches, the appropriate way for delivering QDs into cell should 
be determined according to the specific experimental requirements. The relationship between the 
specific examples and the delivery strategies are listed in Table 1 [66]. Sensors 2011, 11                                       
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Table 1. Selected strategies for the intracellular delivery of QDs. 
Strategy Mechanism  Examples Targeted  Cells  References 
Passive uptake  Electrostatic 
interactions 
- HeLa 
Human macrophages 
Breast cancer (MDA-MB-231) 
Human melanoma cells (LU1205) 
[15] 
[27,72] 
[73,74] 
[75] 
Facilitated delivery  Peptide-mediated 
 
 
 
 
 
 
 
Protein-mediated 
 
 
 
 
 
 
 
 
Polymer/lipid-
mediated 
 
 
 
Drug-mediated 
Small molecule 
 
 
 
 
TAT 
 
 
 
Pep-1 (Chariot) 
 
RGD motify 
 
Neuropeptide 
Transferrin 
Antibody 
EGF 
 
 
 
Cholera toxin B 
NGF 
Lipid polymers 
 
 
Polyethylenei-
mine 
Tiopronin 
Glucose/sugar 
Folate 
Adenine/AMP 
Dopamin 
 
Human embryonic kidney 
HeLa 
Mesenchymal stem cells 
Jurkat cells 
Osteoblast 
Vascular endothelial cells 
Fibroblast (NIH 3T3) 
Epidermoid carcinoma 
HeLa 
Human pancreatic cancer 
Breast cancer (MCF-7) 
Mesenchymal stem cells 
Chinese hamster ovary 
Medulloblastoma tumors 
Glioma tumors 
Fibroblast 
PC12 neural cells 
Mouse lymphoma 
HeLa 
A549 epithelial lung HeLa 
HeLa 
 
Fibroblast 
S. cerevisiae (Baker’s yeast) 
Epidermal carcinoma 
Bacteria (Bacillus subtilis, E. coli) 
A9 mouse fibroblast with 
transfected dopamine receptor 
[76] 
[77] 
[53] 
[28] 
[78] 
[78] 
[79] 
[80] 
[17] 
[2,81,82] 
[11] 
[83] 
[84-86] 
[87] 
[87] 
[88,89] 
[90,91] 
[92] 
[93] 
[94] 
[95] 
 
[96] 
[97,98] 
[99] 
[100,101] 
[102] 
Active Delivery  Electroporation 
 
Microinjection 
- 
 
- 
HeLa 
Mouse neural stem progenitor 
cells 
Xenopus embryo 
HeLa 
Human embryonic kidney 
[71] 
[9] 
[71] 
[103] 
[104] 
4. QDs-Based Cancer Targeting and Imaging  
The photoluminescence (PL) of QDs is exceptionally bright and stable, making them potential 
candidates for biomedical imaging and therapeutic interventions. QDs conjugated with cancer specific 
ligands/antibodies/peptides were found to be effective for detecting and imaging human cancer cells. 
Gao and coworkers [67] firstly reported the QDs-antibody conjugates for in vivo targeting and imaging 
cancer, in which QDs-antibody conjugates were used as imaging probe for investigating and tracing Sensors 2011, 11                                       
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QDs-PSMA antibody conjugates in mouse bearing subcutaneous human prostate cancer. It was found 
that the QDs-antibody conjugates were efficiently and uniformly distributed in prostate tumors due to 
the specific binding between PSMA antigen in prostate cancer cells and PSMA antibody on QDs. Cai 
and coworkers [105] conjugated NIR QDs with RED peptide, which could bind to the over-expressed 
αvβ3 integrin on the surface of U87MG glioblastoma cells and MDA-MB-435 human breast cancer 
cells to target cancer cell in vivo. By linking QDs to AFP (alpha-fetoprotein) antibody, an important 
marker for hepatocellular carcinoma cell lines, a specific immunofluorescent probes was obtained for 
further detection of AFP antibody in human serum. Yu et al. [106] demonstrated that the probe could 
target the specific hepatocellular carcinoma cells, and the expected results was obtained by investigating 
distribution of the probes in cancer cells by using a site-by-site measurement. Weng et al. [107] 
functionalized QDs with anti-HER2 scFv to synthesize the immunoliposome-based nanoparticles   
(QD-ILs). After incubating with HER2-overexpressing SK-BR-3 and MCF-7/HER2 cells, the QD-ILs 
exhibited efficient receptor-mediated endocytosis. In vivo ﬂuorescence imaging showed that QD-ILs 
had localized prominently in tumors as well as in MPS organs (Figure 3). Liu et al. [68] reported a 
QDs-based wavelength-resolved spectral imaging for molecular mapping of tumor heterogeneity on 
human prostate cancer tissue specimens. By conjugating different QDs with specific protein biomarkers, 
such as E-cadherin, high-molecular-weight cytokeratin, p63, and α-methylacyl CoA racemase, structural 
distinct prostate glands and single cancer cells could be detected and characterized within the   
complex microenvironments of radical prostatectomy and needle biopsy tissue specimens using the  
wavelength-resolved spectral imaging.  
Figure 3. ( a) Left panel: In vivo  ﬂuorescence imaging of three nude mice bearing   
MCF-7/HER2 xenografts implanted in the lower back 30 h after i.v. injection with anti-
HER2 QD-ILs; (b) Right panel: A 5 µm section cut from frozen tumor tissues harvested  
at 48 h postinjection and examined by confocal microscopy by a 63× oil immersion objective 
(image size, 146 µm × 146 µm). The tumor section was examined in two-color scanning 
mode for nuclei stained by DAPI (blue) and QD-ILs (red). (Cited from Weng et al. [107]). 
 
(a) (b) 
The main advantage of QDs imaging is that it is non-ionizing and less hazardous [108]. In recent 
years, several groups have used QD probes for ﬂuorescence immunostaining of ﬁxed cells and tissue 
specimens [109-113]. QD-based immunohistochemistry (IHC) can improve both diagnostic sensitivity 
and speciﬁcity. In addition, because multiplexed QD staining can be carried out on intact cells and 
tissue specimens, it is expected to provide correlated molecular and morphological information, at the Sensors 2011, 11                                       
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same time, this type of integrated biomarker and morphological data are not available from traditional 
analytical methods such as mass spectrometry, gene chips, protein microarrays, and polymerase chain 
reactions [109]. However, medical applications of QD-based IHC have achieved only limited success. 
A major bottleneck is the lack of robust protocols to deﬁne the key parameters and steps [109]. For 
example, there are no consensuses on methods for QD-antibody (QD-Ab) bioconjugation, tissue 
specimen preparation, multicolor QD staining, image processing and data quantiﬁcation. So it is 
necessary to solve these problems, and let the QDs move further. 
5. QDs Related Photodynamic Therapy for Cancer 
Presently, the conventional types of cancer treatment (chemotherapy and radiation therapy), work 
by destroying fast-growing cells, but other types of fast-growing healthy cells (such as blood and hair 
cells) also can be damaged along with cancer cells, causing adverse reactions, or side effects. These 
side effects can range from fatigue and flu-like symptoms to hair loss and blood clotting problems. 
PDT developed in last century has become an FDA-approved therapy for different malignancies and 
with potential in other ailments such as coronary heart disease, AIDS and psoriasis [63]. 
Exploration of the use of light-activated drugs known as photosensitizers (PS) has been one of the 
most active areas of photomedical research in recent years [18-21,63,114,115]. PDT uses the 
combination of a photosensitizing drug and light in the presence of oxygen to cause selective damage 
to the targeting tissue. During PDT, reactive oxygen intermediates (ROI) is generated in the diseased 
cells by a simple and controllable light-activated process, which involves a photosensitizer that is 
capable of absorbing light appropriate wavelength and transfers energy or electron to oxygen or other 
molecules, and creates ROI such as singlet oxygen (
1O2), hydroxyl radical (OH), super oxide anion 
(O2
−) and hydrogen peroxide (H2O2). Then ROI will immediately react with vital biomolecules   
in cell organelles, leading to cell damage, mutation, death and photooxidation of cell   
constituents [19,20,63,114,115]. Singlet oxygen (
1O2) is regarded as the main mediator of   
photo-induced cytotoxicity in PDT, which causes oxidation and degradation of cellular components, 
and ultimately cell apoptosis. [20,63,114,115] (Figure 4).  
Figure 4. Schematic representation of possible mechanisms for induction of PDT processes 
by QDs and the classical photosensitizer. 
 
The standard PS drugs for PDT are porphyrin, phthalocyanines and chlorine derivatives. Porphyrin 
derivatives are the first generation photosensitizer. Despite the clinical success of porphyrin Sensors 2011, 11                                       
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derivatives, some of their disadvantages like prolonged cutaneous photosensitivity, chemical impurity 
and weak absorption at therapeutic wavelengths have inspired the development of new PDT 
photosensitizers with improved optical and chemical properties. Phthalocyanines derivatives have 
favorable photophysical and chemical properties, which include strong absorbance at long wavelengths 
and chemical tunability through substituent addition on the periphery of the macrocycle or on the axial 
ligands. However, like most photosensitizing agents, these PS have poor solubility in water and tend to 
aggregate in aqueous solutions, which can result in loss of photochemical activity and affect their cell 
penetrating properties [63]. To resolve such issues nanoparticles are currently being explored as potential 
delivery systems for PDT photosensitizers or directly as PDT agents. The novel QDs-PS conjugates 
are used as a high ratio of PDT agents and anticancer targeting antibodies, where QDs can act as 
nanoscaffolds and solubilizers. They can also function as “energy-harvesting antenna” for PDT therapy 
due to their large one- or two-photon absorption cross-sections. Thus, QDs can be efficiently exited 
even deep within tissues and sensitized proximal PDT agents via energy transfer from QDs to PDT [21]. 
The novel QDs-PS conjugates showed many advantages over conventional PS drugs [17-21,63,114,115]: 
(1) they are species with well-defined size, shape, and composition, and can be synthesized by relatively 
simple and inexpensive methods; (2) they have been shown to be nontoxic in the absence of light but 
have the potential to be cytotoxic under irradiation; (3) they have photostability, and tunable and strong 
absorption, which can be tuned from the UV their composition and size; (4) the surface coating of QDs 
can be modified to enable them to become water soluble, biocompatible and target-specific. 
However, researchers should be further investigated on the basis of predominances of the QDs-PS 
compared to the convention PS drugs. Despite many desirable properties of QDs for PDT, there still 
remain several important issues that need to be addressed to fully assess their applicability as PS in 
PDT. One major issue is the toxicity profile of the QDs inside the cells and their overall photostability 
once exposed to biological environments [63]. Another important matter that should be carefully 
investigated is how their surface composition affects the photosensitization process. Still, QDs-PS 
conjugates for cancer therapy are only suitable to superficial tumours is also need to be resolved [18]. 
6. Conclusions and Outlook 
In the last decade, the unique photophysical properties and functions of QDs have been widely 
investigated, making them one of the most promising nanomaterials. Their outstanding performances 
such as high fluorescence yields, stability against photobleaching and the size-dependent luminescence 
features of QDs provide broad variety of applications for QDs in many fields. By acting as fluorescent, 
and photoelectrochemical as well as electrochemical probes, various QDs-based optical and 
electrochemical bioanalysis have already been successfully explored for sensing a wide range of 
molecules with high sensitivity and specificity. Furthermore, as a biomedical label, QDs can make a 
worthy contribution to the development of new diagnostic and delivery systems due to their unique 
optical properties. By combination of functional biomolecule-nanoparticle hybrid systems and the 
optical imaging and biophysics, QDs have been used as optical reporter units of biocatalytic 
transformations and can probe intracellular processes in vitro. QDs as a novel probe for in vivo 
analysis and clinic therapy such as PDT open an attractive new field with promising prospectives  
in biomedicine. Sensors 2011, 11                                       
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